Abstract
Two groups of schizophrenic outpatients were treated with perphenazine decanoate (N=20) andcis(z)-flupentixol decanoate (N=24) respectively. Every 3 months the dose was gradually reduced until symptoms appeared that were suggestive of a prodromal phase of a psychotic episode. A slightly higher dose was then promptly reinstituted (the minimum effective dose). At each dose level, two blood samples were drawn for determination of serum concentration. The mean minimum effective dose of perphenazine decanoate was 99.3 mg/2 weeks (range 21.6–270.5), while the mean minimum effective dose ofcis(z)-flupentixol decanoate was 60 mg/2 weeks (range 20–250). The corresponding mean serum level of perphenazine decanoate was 7.3 nmol/l (range 2.0–18.1) and ofcis(z)-flupentixol decanoate 7.8 nmol/l (range 1.2–37.0). There was a significant correlation between the administered doses and the corresponding serum levels for both drugs (r=0.87,P<0.01). A weak positive correlation was found between serum levels at the minimum effective dose and symptom intensity (BPRS total score) (r=0.53,P<0.02) for perphenazine, but notcis(z)-flupentixol. No correlation was found between serum levels and side effects or length of neuroleptic treatment. It is concluded that the serum drug concentrations corresponding to the lowest effective dose are so variable that routine serum level monitoring may be of limited value in the long-term maintenance treatment of schizophrenia.
Similar content being viewed by others
References
Aaes-Jørgensen T (1980) Specific high-performance liquid chromatographic method for estimation of thecis(Z)- and trans(E)-isomers of clopenthixol and a N-dealkyl metabolite. J Chromatogr 183:239–245
Balant-Gorgia AE, Eisele R, Aeschliemann JM, Balant LP, Garrone G (1985) Plasma flupenthixol concentrations and clinical response in acute schizophrenia. Ther Drug Monit 7:411–414
Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79–91
Bjørndal F, Aaes-Jørgensen T (1984) Serumconcentration in acute paranoid psychoses treated withcis(Z)-clopenthixol. Nord Psychiatr Tidsskr 38:229–233
Bolvig Hansen L, Larsen N-E (1977) Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology 53:306–309
Bolvig Hansen L, Larsen N-E, Vestergård P (1981) Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology 74:306–309
Bolvig Hansen L, Larsen N-E, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychosis. Psychopharmacology 78:112–115
Browne FWA, Cooper SJ, Wilson R, King DJ (1988) Serum haloperidol levels and clinical response in chronic, treatment-resistant schizophrenic patients. J Pharmacol 2:94–103
Carpenter WT, Heinrichs DW (1983) Early intervention, time-limited, targeted pharmacotherapy of schizophrenia. Schizophr Bull 9:533–542
Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV (1990) Intermittent vs maintenance medication in schizophrenia. Clin Neuropharmacol 13 [suppl 2]:426–427
Jørgensen A (1978) A sensitive and specific radioimmunoassay forcis(Z)-flupenthixol in human serum. Life Sci 23:1533–1542
Kane JM, Liebermann JA (1987) Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1103–1109
Kane JM, Rifkin A, Woerner M, Reardon G, Kreisman D, Blumenthal R, Borenstein M (1985) High-dose versus low-dose strategies in the treatment of schizophrenia. Psychopharmacol Bull 21:533–537
Kirk L, Bilde A, Stauning JA, Ahrensburg B, Petersen E, Jørgensen A (1984) Serum concentrations ofcis(z)-flupenthixol in patients under maintenance treatment withcis(z)-flupenthixol decanoate. Nord Psychiatr Tidsskr 38:493–505
Knudsen P, Hansen LB, Højholdt K, Larsen N-E (1985) Long-term depot treatment with perphenazine decanoate I. Acta Psychiatr Scand (suppl) 72:29–40
Larsen N-E, Bolvig Hansen L, Knudsen P (1985) Quantitative determination of perphenazine and its dealcylated metabolites using high-performance liquid chromatographic method. J Chromatogr 341:244–250
Liebermann JA, Kane JM (1986) Predictors of relapse in schizophrenia. American Psychiatric Press, Washington
Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) Side effects of neuroleptics: The UKU side effect rating scale. Acta Psychiatr Scand 76 [suppl 334]
Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PRA (1987) Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two year outcome. Arch Gen Psychiatry 44:518–521
Midha K, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1987) The search for correlations between neuroleptic plasma levels and clinical outcome: a critical review. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1341–1351
Overall J, Gorham D (1962) Brief Psychiatric Rating Scale. Psychol Rep 10:799–812
Saikia JK, Jørgensen A (1983) Steady-state serum concentrations aftercis(z)-flupenthixol decanoate in Viscoleo. Psychopharmacology 80:371–373
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kistrup, K., Gerlach, J., Aaes-Jørgensen, T. et al. Perphenazine decanoate andcis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Psychopharmacology 105, 42–48 (1991). https://doi.org/10.1007/BF02316862
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02316862